Breadcrumb

John Greiner, Ph.D.

John W. Greiner, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
  • Building 10, Room 8B04
  • Bethesda, MD 20892-1750
  • 240-858-3451
  • jg117s@nih.gov
Center for Immuno-Oncology

RESEARCH SUMMARY

The Animal Protocols Facility is responsible for the assessment and oversight of the Center for Immuno-Oncology (CIO) Animal Care & Use Program components, compliance required by the NCI-ACUC guidelines, AALAC accreditation and facilities, including the review and approval of animal research protocols, evaluation of animal use and housing areas, monitoring and evaluation of animal use practices, review and approval of policies and standards for animal care and use, and investigation of animal welfare concerns. Additionally, the group is responsible for the management of several mouse colonies, which include transgenic mice and mice harboring genetic mutations, that results in the development of spontaneous tumors to be made available to many investigators within the CIO for preclinical studies.

Areas of Expertise

Immunology
Immunotherapy

Publications

Selected Publications

Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein

Morillon YM 2nd, Hammond SA, Durham NM, Schlom J, Greiner JW.
Oncotarget. 8: 73469-82, 2017. [ Journal Article ]

Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody

Fallon JK, Vandeveer AJ, Schlom J, Greiner JW.
Oncotarget. 8: 20558-71, 2017. [ Journal Article ]

Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor

Vandeveer AJ, Fallon JK, Tighe R, Sabzevari H, Schlom J, Greiner JW.
Cancer Immunol Res. 4: 452-62, 2016. [ Journal Article ]

The immunocytokine NHS-IL12 as a potential cancer therapeutic

Fallon J, Tighe R, Kradjian G, Guzman W, Bernhardt A, Neuteboom B, Lan Y, Sabzevari H, Schlom J, Greiner JW.
Oncotarget. 5: 1869-84, 2014. [ Journal Article ]

Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice

Zeytin HE, Patel AC, Rogers CJ, Canter D, Hursting SD, Schlom J, Greiner JW.
Cancer Res.. 64: 3668-78, 2004. [ Journal Article ]

Team

LaJuan Chase
Animal Technician (Contr.)
Lajuan Chase
Animal Technician (Contr)
Elmer Contreras
Emily Gonzalez
Animal Technician (Contr)
Emily Gonzalez